Unacceptably high risk of serious liver symptoms in certain patient groups (women with CD4 count >250 and men >400) has led the U.S. DHHS to recommend the restriction of nevirapine use to those at lower risk, unless the benefit to the patient clearly outweighs the risk; although in the 2NN study which found these CD4 limits, the effect was seen only in patients recruited from Thailand.
Siamo giunti, oggi, alla seconda lettura e, scorrendo il documento che ci è stato sottoposto, si nota che sono stati ripresentati gli stessi emendamenti che avevamo proposto in prima lettura.WikiMatrix WikiMatrix